effect liqurice in treatment of schizophernia

Effect of licorice (Glycyrrhiza glabra) versus placebo on increasing the efficiency of antipsychotics in women with chronic schizophrenia, a double-blind clinical trials

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111105008013N2

Enrollment

Registered

2018-08-26

Start date

2018-01-21

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: one tablet of D-Reglis (IRAN DAROUK Co., Tehran, Iran) containing 380 mg of standardized dried licorice extract for 8 weeks and three times a day. Intervention 2: I

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Active schizophrenia Met DSM-IV criteria for chronic schizophrenia Drug regimen of risperidone (6 mg/day), cetirizine (4 mg/day)

Exclusion criteria

Exclusion criteria: Bipolar disorder Borderline-schizotypal-Antisocial personality disorder ?Eating disorder Alcohol and drug (other than schizophrenia drugs) abuse in the past month Suicide or suicidal ideation History of neurologic and systemic disorders Thyroid dysfunction Administration of antidepressants and Anti-anxiety drugs Steroids (such as oral contraceptives) Use of MAO-I drugs Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Positive symptoms; Negative symptoms; General psychopathological symptoms. Timepoint: Start intervention and a month later. Method of measurement: PANSS score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Siahpoosh

Ahvaz University of Medical Sciences

siahpoosh-a@ajums.ac.ir+98 61 3334 2197

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026